Skip to main navigation
Repare Therapeutics
  • Company
    • About Us
    • Leadership
    • Partnering
    • Contact
  • Science
    • Discovery Platform
    • Therapeutic Focus
    • Scientific References
  • Pipeline
    • Development Pipeline
    • Camonsertib ATR Inhibitor
    • Lunresertib PKMYT1 Inhibitor
    • Polθ Inhibitor
  • Clinical Trials
    • Clinical Trials Overview
  • Careers
    • Job Opportunities
    • Our Culture
  • Investors & Media
    • Corporate Profile
    • Press Releases
    • Events & Presentations
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Management Team
      • Board of Directors
      • Committee Composition
      • Contact the Board
      • Entity report pursuant to Bill S-211
    • Investor Resources
      • Investor FAQs
      • Investor Email Alerts
      • PFIC Statement
      • Contact IR
Select Page

Press Releases

Press Releases

Feb 15, 2024
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
Feb 12, 2024
Repare Therapeutics to Regain Global Rights to Camonsertib
Jan 25, 2024
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
Jan 08, 2024
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
Jan 04, 2024
Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Page 2
  • Current page 3
Displaying 21 - 25 of 25
Media & IR Contact
Investor Relations & Media Contact

Robin Garner
Investor Relations
Contact Us

Helpful Tools
  • Print Page
  • Email Alerts
  • RSS Feeds
Company
  • About Us
  • Leadership
  • Partnering
  • Contact
Science
  • Discovery Platform
  • Therapeutic Focus
  • Scientific References
Pipeline
  • Development Pipeline
  • Camonsertib ATR Inhibitor
  • Lunresertib PKMYT1 Inhibitor
  • Polθ Inhibitor
Clinical Trials
  • Clinical Trials Overview
Careers
  • Job Opportunities
  • Our Culture
Investors & Media
  • Corporate Profile
  • Press Releases
  • Events & Presentations
  • Stock Information
  • SEC Filings
  • Corporate Governance
  • Investor Resources
Repare Therapeutics logo
© 2024 Repare Therapeutics
  • Privacy Policy
  • Terms of Use
  • Cookie Policy